Soligenix, Inc. (SNGX)
| Market Cap | 8.20M -36.4% |
| Revenue (ttm) | n/a |
| Net Income | -10.24M |
| EPS | -1.01 |
| Shares Out | 21.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 139,771 |
| Open | 0.3778 |
| Previous Close | 0.3800 |
| Day's Range | 0.3748 - 0.3900 |
| 52-Week Range | 0.2800 - 3.2200 |
| Beta | 1.92 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About SNGX
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment ... [Read more]
Financial Performance
Financial StatementsNews
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare di...
Soligenix Quarterly report: Q2 2026
Soligenix has published its Q2 2026 quarterly earnings report on August 7, 2026.
Soligenix Proxy statement: Proxy filing
Soligenix filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Soligenix Proxy statement: Proxy filing
Soligenix filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Soligenix Proxy statement: Proxy filing
Soligenix filed a proxy statement on July 23, 2026, providing details for shareholder voting and corporate governance matters.
Soligenix Proxy statement: Proxy filing
Soligenix filed a proxy statement on July 21, 2026, providing details for shareholder voting and corporate governance matters.
Soligenix to apply for vaccine development funding for Bundibugyo Ebola vaccine
Soligenix (SNGX) noted that the Coalition for Epidemic Preparedness Innovations has announced a call for proposal for vaccine development for Bundibugyo virus with applications due June 12. Soligenix,...
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development PRINCETON, N.J., June 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasd...
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
Thermostability, immunogenicity and efficacy data against related virusesmay provide rapid starting point for vaccine development PRINCETON, N.J., May 26, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq:...
Soligenix reports Q1 EPS (28c) vs. (97c) last year
“We remain disappointed with the unanticipated outcome of the FLASH2 study,” stated Christopher Schaber, PhD, President and CEO of Soligenix (SNGX). “Despite the fact that HyBryte demonstrated statist...
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...
Soligenix Quarterly report: Q1 2026
Soligenix has published its Q1 2026 quarterly earnings report on May 8, 2026.
Soligenix Earnings release: Q1 2026
Soligenix released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Soligenix price target lowered to $1.50 from $10 at Alliance Global
Alliance Global lowered the firm’s price target on Soligenix (SNGX) to $1.50 from $10 and keeps a Buy rating on the shares after the Data Monitoring Committee recommended halting the…
Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma
Soligenix (SNGX) announced that the Data Monitoring Committee completed the interim efficacy analysis of its pivotal Phase 3 FLASH2 trial evaluating HyBryte – Synthetic Hypericin – in the treatment of...
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
PRINCETON, N.J., April 28, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Soligenix Slides: Corporate presentation
Soligenix has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial
Soligenix (SNGX) announced today that the positive results of its comparability study evaluating HyBryte – synthetic hypericin – versus Valchlor – mechlorethamine – for the treatment of cutaneous T-ce...
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
HyBryte™ demonstrates more rapid and robust treatment response compared toValchlor ® during 12-week treatment course PRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soli...
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Upcoming high-impact milestones include interim analysis in Q2 2026 and top-line results in H2 2026 from HyBryte™ trial PRINCETON, N.J., March 31, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (...
Soligenix Annual report: Q4 2025
Soligenix has published its Q4 2025 annual report on March 31, 2026.
Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease
Soligenix (SNGX) announced that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products, has granted orphan drug desig...
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
PRINCETON, N.J., March 26, 2026 /PRNewswire/ --Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...
Soligenix Slides: Corporate presentation
Soligenix has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
Highlighting Positive Results in Comparison to Valchlor ® and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...